Access to Fungal Diagnostics in India: Findings of a Nationwide Survey
Journal of Clinical Infectious Disease Society · 2026-07 · 4 (3) · 230-234
DOI: 10.4103/cids.cids_37_26 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Infectious Disease Society, online erschienen am 05.08.2026. Verfasst von Parikshit Shirish Prayag und 3 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Invasive fungal infections (IFIs) are associated with substantial morbidity and mortality and represent a major healthcare challenge in India. Timely diagnosis is critical for optimal management, but the availability of advanced fungal diagnostics across the country remains uncertain. This nationwide survey assessed the current status of fungal diagnostic facilities in India and identified existing gaps.
Methods
A structured questionnaire evaluating laboratory infrastructure, diagnostic capabilities, availability of antifungal susceptibility testing (AFST), fungal biomarkers, molecular diagnostics, and therapeutic drug monitoring (TDM) was distributed electronically to microbiologists and infectious disease physicians across India.
Results
Representatives from 111 of 120 contacted centers responded. While routine fungal cultures were widely available, advanced diagnostic capabilities remained limited. Fewer than 60% of centers had a dedicated mycology laboratory. MALDI-TOF mass spectrometry was used in 18.4% and 19.0% of laboratories for identification of yeasts and molds, respectively, while only seven centers performed internal transcribed spacer sequencing. Mold AFST was available in only 14 laboratories. Access to specialized staining techniques, molecular assays for Pneumocystis jirovecii , and diagnostics for endemic mycoses was limited. Galactomannan and (1→3) β-D-glucan assays were available in 41.4% and 33.3% of the centers, respectively, indicating some improvement from previously published surveys. However, rapid turnaround times and TDM services remained uncommon.
Conclusions
Despite measurable progress, access to comprehensive fungal diagnostics in India remains limited. Strengthening laboratory infrastructure, expanding expertise, and improving access to advanced diagnostic technologies are essential to optimize the diagnosis and management of IFIs.
Zitieren
APA
Prayag, P. S., Patwardhan, S. A., Kadam, M., & Prayag, A. P. (2026). Access to Fungal Diagnostics in India: Findings of a Nationwide Survey. Journal of Clinical Infectious Disease Society, 4(3), 230-234. https://doi.org/10.4103/cids.cids_37_26
Vancouver
Prayag PS, Patwardhan SA, Kadam M, Prayag AP. Access to Fungal Diagnostics in India: Findings of a Nationwide Survey. Journal of Clinical Infectious Disease Society. 2026;4(3):230-234. doi:10.4103/cids.cids_37_26
BibTeX
@article{Prayag2026,
author = {Prayag, Parikshit Shirish and Patwardhan, Sampada Ajeet and Kadam, Mousami and Prayag, Amrita P.},
title = {Access to Fungal Diagnostics in India: Findings of a Nationwide Survey},
journal = {Journal of Clinical Infectious Disease Society},
year = {2026},
volume = {4},
number = {3},
pages = {230--234},
doi = {10.4103/cids.cids_37_26}
}
EUVIMED